Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

In vitro chemoresponse analysis of cervical cancer patient specimens.

Grigsby PW, Gan CM, Tillmanns TD, Del Priore G.

Int J Gynecol Cancer. 2014 Nov;24(9):1665-74. doi: 10.1097/IGC.0000000000000186.

PMID:
24987911
2.

In vitro chemoresponse to cisplatin and outcomes in cervical cancer.

Grigsby PW, Zighelboim I, Powell MA, Mutch DG, Schwarz JK.

Gynecol Oncol. 2013 Jul;130(1):188-91. doi: 10.1016/j.ygyno.2013.04.005. Epub 2013 Apr 10.

3.

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.

Rosen VM, Guerra I, McCormack M, Nogueira-Rodrigues A, Sasse A, Munk VC, Shang A.

Int J Gynecol Cancer. 2017 Jul;27(6):1237-1246. doi: 10.1097/IGC.0000000000001000. Review.

4.

In vitro chemoresponse in metachronous pairs of gyneclologic cancers.

Dalton HJ, Fiorica J, McClure CK, Rocconi RP, Recio FO, Levocchio JL, Burrell MO, Monk BJ.

Gynecol Oncol Res Pract. 2014 Dec 6;1:7. doi: 10.1186/2053-6844-1-7. eCollection 2014.

5.

The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy.

Mabuchi S, Morishige K, Fujita M, Tsutsui T, Sakata M, Enomoto T, Kimura T.

Gynecol Oncol. 2009 May;113(2):200-4. doi: 10.1016/j.ygyno.2009.02.008. Epub 2009 Mar 6.

PMID:
19268342
6.

A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.

Kitagawa R, Katsumata N, Ando M, Shimizu C, Fujiwara Y, Yoshikawa H, Satoh T, Nakanishi T, Ushijima K, Kamura T.

Gynecol Oncol. 2012 May;125(2):307-11. doi: 10.1016/j.ygyno.2012.02.009. Epub 2012 Feb 12.

PMID:
22333993
7.

A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.

Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, Spannuth WA, Gold MA.

Gynecol Oncol. 2007 May;105(2):299-303. Epub 2007 Feb 14.

PMID:
17303230
8.

Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

Karageorgopoulou S, Kostakis ID, Gazouli M, Markaki S, Papadimitriou M, Bournakis E, Dimopoulos MA, Papadimitriou CA.

BMC Cancer. 2017 Jun 28;17(1):451. doi: 10.1186/s12885-017-3435-x.

9.

Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.

Hisamatsu T, Mabuchi S, Yoshino K, Fujita M, Enomoto T, Hamasaki T, Kimura T.

Int J Gynecol Cancer. 2012 May;22(4):623-9. doi: 10.1097/IGC.0b013e3182473277.

PMID:
22343974
10.

Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial.

Downs LS Jr, Chura JC, Argenta PA, Judson PL, Ghebre R, Geller MA, Carson LF.

Gynecol Oncol. 2011 Feb;120(2):265-9. doi: 10.1016/j.ygyno.2010.10.020. Epub 2010 Dec 8.

PMID:
21145100
11.

First-line paclitaxel and carboplatin in persistent/recurrent or advanced cervical cancer: a retrospective analysis of patients treated at Brazilian National Cancer Institute.

Garces ÁH, Mora PA, Alves FV, do Carmo CC, Grazziotin R, Fernandes AC, Nogueira-Rodrigues A, de Melo AC.

Int J Gynecol Cancer. 2013 May;23(4):743-8. doi: 10.1097/IGC.0b013e31828c141d. Erratum in: Int J Gynecol Cancer. 2013 Jun;23(5):978.

PMID:
23552805
12.
13.

Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.

Dimopoulos MA, Papadimitriou CA, Sarris K, Aravantinos G, Kalofonos C, Gika D, Gourgoulis GM, Efstathiou E, Skarlos D, Bafaloukos D.

Gynecol Oncol. 2002 Jun;85(3):476-82.

PMID:
12051877
14.

Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.

Song M, DiPaola RS, Cracchiolo BM, Gibbon DG, Hellmann M, Nieves-Neira W, Vaidya A, Wagreich AR, Shih WJ, Rodriguez-Rodriguez L.

Int J Gynecol Cancer. 2014 Nov;24(9):1636-41. doi: 10.1097/IGC.0000000000000258.

15.

Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.

Tiersten AD, Selleck MJ, Hershman DL, Smith D, Resnik EE, Troxel AB, Brafman LB, Shriberg L.

Gynecol Oncol. 2004 Feb;92(2):635-8.

PMID:
14766258
16.

Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, Lee JJ, Ang KK, Lippman SM, Hong WK.

Cancer. 2001 Apr 1;91(7):1316-23.

PMID:
11283932
17.

Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.

Nishio S, Kitagawa R, Shibata T, Yoshikawa H, Konishi I, Ushijima K, Kamura T.

Cancer Chemother Pharmacol. 2016 Oct;78(4):785-90. doi: 10.1007/s00280-016-3133-4. Epub 2016 Aug 23.

PMID:
27553435
18.

Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer.

Lorusso D, Mainenti S, Pietragalla A, Fusco E, Malaguti P, Masciullo V, Scambia G.

Oncology. 2011;80(5-6):390-4. doi: 10.1159/000330537. Epub 2011 Aug 5.

PMID:
21829040
19.

Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.

Chitapanarux I, Tonusin A, Sukthomya V, Charuchinda C, Pukanhapan N, Lorvidhaya V.

Gynecol Oncol. 2003 Jun;89(3):402-7.

PMID:
12798702
20.

A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.

Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ.

Gynecol Oncol. 2009 Jan;112(1):85-9. doi: 10.1016/j.ygyno.2008.09.029. Epub 2008 Nov 1.

Supplemental Content

Support Center